Views of Wall Street’s Leading Experts on Revelation Biosciences Inc.

Revelation Biosciences Inc. (NASDAQ: REVB) stock fell -6.10% on Friday to $0.56 against a previous-day closing price of $0.60. With 3.16 million shares changed hands, the volume of the stock remained lighter than its average volume of 4.84 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.5899 whereas the lowest price it dropped to was $0.5132. The 52-week range on REVB shows that it touched its highest point at $11.29 and its lowest point at $0.40 during that stretch. It currently has a 1-year price target of $9.00.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of REVB was down-trending over the past week, with a drop of -13.38%, but this was down by -10.02% over a month. Three-month performance dropped to -40.47% while six-month performance fell -78.83%. The stock lost -94.37% in the past year, while it has lost -94.48% so far this year. A look at the trailing 12-month EPS for REVB yields -2.28 with Next year EPS estimates of -0.69. For the next quarter, that number is -0.14. This implies an EPS growth rate of -553.40% for this year and -15.80% for next year.

Float and Shares Shorts:

At present, 14.20 million REVB shares are outstanding with a float of 8.84 million shares on hand for trading. On Jul 14, 2022, short shares totaled 0.27 million, which was 1.78% higher than short shares on Jun 14, 2022. In addition to Mr. James M. Rolke as the firm’s CEO & Director, Mr. Chester Stanley Zygmont III serves as its Chief Financial Officer.

Institutional Ownership:

Through their ownership of 38.93% of REVB’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 6.79% of REVB, in contrast to 17.73% held by mutual funds. Shares owned by individuals account for 0.27%. As the largest shareholder in REVB with 5.42% of the stake, Monashee Investment Management LL holds 817,562 shares worth 817,562. A second-largest stockholder of REVB, Citadel Advisors LLC, holds 42,633 shares, controlling over 0.28% of the firm’s shares. Bridgeway Capital Management LLC is the third largest shareholder in REVB, holding 39,800 shares or 0.26% stake. With a 0.26% stake in REVB, the Bridgeway Ultra Small Company Fun is the largest stakeholder. A total of 39,800 shares are owned by the mutual fund manager. The Fidelity Nasdaq Composite Index F, which owns about 0.01% of REVB stock, is the second-largest Mutual Fund holder. It holds 1,542 shares valued at 1712.0. First Trust Alternative Opportuni holds 0.00% of the stake in REVB, owning 0 shares worth 0.0.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2022, REVB reported revenue of $0.00 and operating income of -$6.59M. The EBITDA in the recently reported quarter was -$6.58M and diluted EPS was -$0.47.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for REVB since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With REVB analysts setting a high price target of $9.00 and a low target of $9.00, the average target price over the next 12 months is $9.00. Based on these targets, REVB could surge 1507.14% to reach the target high and rise by 1507.14% to reach the target low. Reaching the average price target will result in a growth of 1507.14% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. REVB will report FY 2022 earnings on 03/01/2023. Analysts have provided yearly estimates in a range of -$0.87 being high and -$0.87 being low. For REVB, this leads to a yearly average estimate of -$0.87. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Revelation Biosciences Inc. surprised analysts by -$0.33 when it reported -$0.47 EPS against a consensus estimate of -$0.14. Based on analyst estimates, the high estimate for the next quarter is -$0.14 and the low estimate is -$0.14. The average estimate for the next quarter is thus -$0.14.



Summary of Insider Activity:

Insiders traded REVB stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 8 while that of sell transactions has risen to 1 over the past year. The total number of shares bought during that period was 153,000 while 731,950 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *